“Impact of the modulator elexacaftor/tezacaftor/ivacaftor (ETI) on the complexity of prescriptions and the clinical stage of children and adolescents with cystic fibrosis” (2026) Research, Society and Development, 15(1), p. e7715150550. doi:10.33448/rsd-v15i1.50550.